fast
spread
novel
coronaviru
becom
global
threat
hit
worldwid
fragil
health
care
system
itali
continu
growth
case
death
requir
control
measur
correct
manag
epidemiolog
emerg
contribut
increas
overal
knowledg
systemat
test
gener
popul
requir
describ
first
italian
survey
perform
employe
belong
motherchild
research
hospit
test
viral
nasopharyng
oropharyng
swab
antibodi
presenc
individu
divid
three
risk
categori
high
medium
low
accord
job
activ
one
subject
posit
swab
test
cohort
posit
presenc
antibodi
result
highlight
presenc
posit
antibodi
significantli
associ
high
medium
risk
exposur
occup
well
cold
conjunct
symptom
respect
moreov
among
healthcar
profession
categori
medic
doctor
show
signific
associ
presenc
antibodi
final
detect
rapid
decreas
antibodi
intens
two
assess
perform
within
short
period
overal
present
studi
increas
knowledg
epidemiolog
data
infect
itali
suggest
high
preval
immun
individu
ie
least
among
atrisk
categori
efficaci
combin
diagnost
protocol
monitor
possibl
outbreak
coronavirus
cov
larg
famili
virus
common
peopl
mani
anim
speci
includ
camel
cattl
cat
bat
anim
coronavirus
rare
infect
human
spread
peopl
except
middl
east
respiratori
syndrom
merscov
sever
acut
respiratori
syndromecoronaviru
sarscov
caus
ongo
pandem
viru
novel
coronaviru
character
linear
positivesens
singlestrand
rna
genom
similar
sarscov
genom
moreov
high
level
homolog
sarslik
coronaviru
isol
bat
pangolin
suggest
first
origin
bat
pangolin
intermedi
host
human
strong
similar
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
sequenc
european
chines
patient
suggest
recent
singl
emerg
viru
anim
reservoir
wwwgisaidorg
two
million
report
case
confirm
death
time
write
see
http
wwwworldometersinfocoronaviru
current
main
challeng
human
be
worldwid
itali
posit
case
th
april
rate
second
worldwid
countri
highest
number
death
mainli
age
group
thu
possibl
contribut
factor
influenc
mortal
rate
could
overal
popul
age
ie
oldest
european
countri
around
elderli
resid
relat
comorbid
howev
high
rate
infect
specif
italian
geograph
area
eg
lombardi
region
might
exclus
relat
age
moment
vaccin
approv
special
treatment
drug
investig
clinic
trial
exist
repurpos
drug
ie
remdesivir
hydroxychloroquin
alphainterferon
ifn
sever
novel
agent
target
key
virushost
interact
despit
common
symptom
onset
diseas
fever
cough
tired
high
clinic
heterogen
fact
infect
show
differ
clinic
manifest
base
patient
age
health
condit
ie
statu
patient
immun
system
gender
addit
variabl
mortal
rate
respons
treatment
like
associ
yet
elucid
host
genet
contribut
although
countri
know
real
number
infect
peopl
total
awar
infect
statu
test
peopl
anyway
seem
establish
overal
number
peopl
posit
molecular
test
ie
confirm
case
total
number
infect
peopl
expect
much
higher
consequ
lack
data
predict
spread
rate
infect
result
global
impact
public
health
concern
world
health
organ
classifi
confirm
case
person
laboratori
confirm
infect
http
reliabl
test
data
therefor
necessari
better
assess
valid
inform
relat
pandem
spread
posit
case
death
immun
individu
moreov
appar
lack
systemat
test
protocol
countri
repres
main
sourc
discrep
mortal
rate
test
perform
follow
viral
test
ie
establish
whether
individu
current
infect
b
serolog
ie
prove
host
immun
antibodi
respons
viru
known
serolog
test
effect
tool
target
immun
popul
also
date
viral
spread
popul
far
europ
comprehens
detail
regularli
updat
data
avail
select
countri
iceland
estonia
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
http
ourworldindataorgcovidtest
howev
mani
nation
includ
itali
accur
epidemiolog
data
serolog
test
present
evalu
contribut
fill
gap
increas
knowledg
pandem
itali
decid
carri
survey
employe
one
nation
research
hospit
ircc
burlo
garofolo
locat
triest
northeastern
itali
overal
number
employe
recruit
test
viral
antibodi
test
short
timefram
one
week
order
minim
possibl
bias
studi
design
multivari
analysi
includ
person
work
risk
exposur
well
healthi
statu
includ
relat
symptom
perform
extrem
interest
result
obtain
studi
detail
suggest
first
time
efficaci
combin
test
strategi
monitor
spread
highlight
immun
specif
reactiv
peopl
repres
quit
high
number
geograph
area
survey
carri
part
mandatori
integr
healthmed
high
exposur
risk
hr
occup
frontlin
healthcar
profession
eg
intens
care
unit
emerg
depart
nurs
perform
daili
procedur
patient
healthcar
oper
provid
medic
transport
patient
transport
biolog
materi
medium
exposur
risk
mr
occup
nonfrontlin
healthcar
profession
laboratori
personnel
collect
handl
specimen
patient
low
exposur
risk
lr
occup
administr
staff
hospit
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
presenc
test
use
neoplextm
detect
kit
assay
accord
manufactur
instruct
qualit
vitro
assay
allow
simultan
detect
n
rdrp
gene
coronaviru
genom
respiratori
specimen
use
realtim
revers
transcript
polymeras
chain
reaction
rtpcr
genematrix
inc
republ
korea
regard
evalu
immun
respons
comparison
choos
best
rapid
kit
carri
compar
three
commerci
avail
one
wantai
sar
presenc
band
consid
posit
p
signal
detect
slightli
minut
recommend
test
consid
studi
borderlin
b
kit
perform
declar
sensit
specif
test
recommend
serum
volum
ad
specimen
well
individu
test
cassett
follow
addit
suppli
buffer
accord
manufactur
instruct
addit
simpl
quantif
amount
signal
antibodi
test
perform
use
imag
j
quantif
tool
http
imagejnihgovijdocstoolshtml
statist
analys
perform
r
http
wwwrprojectorg
quantit
variabl
describ
median
interquartil
rang
iqr
categor
variabl
express
number
employe
percentag
wilcoxon
test
use
compar
continu
variabl
antibodi
group
regard
categor
variabl
chisquar
test
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
fisher
exact
test
use
appropri
investig
healthcar
profession
categori
logist
regress
model
adjust
sex
age
exposur
risk
use
assess
possibl
risk
increas
antibodi
presenc
categori
medic
doctor
perform
test
twotail
statist
signific
set
pvalu
overal
volunt
employe
recruit
enrol
studi
fill
dedic
questionnair
underw
nasopharyng
oropharyng
swab
plu
venipunctur
antibodi
test
supplementari
tabl
age
rang
year
old
sex
distribut
women
male
supplementari
tabl
divid
employe
accord
risk
exposur
individu
includ
hr
group
mr
lr
one
respect
strongli
posit
antibodi
p
result
obtain
femal
nine
male
femal
male
gave
borderlin
data
b
overal
positiveborderlin
pb
categori
repres
whole
sampl
neg
n
one
cohort
report
tabl
median
age
significantli
lower
individu
pb
antibodi
compar
individu
n
antibodi
ie
wilcoxon
test
apart
one
individu
pb
subject
neg
presenc
viru
nasopharingealoropharing
test
moreov
show
sign
symptom
sampl
time
proport
refer
absenc
sign
symptom
question
answer
medic
questionnair
last
three
month
ie
true
asymptomat
final
among
pb
subject
refer
presenc
least
one
signsymptom
medic
histori
questionnair
statist
signific
associ
detect
cold
conjunct
chisquar
test
pvalu
pvalu
respect
matter
fact
last
three
month
pb
subject
suffer
cold
conjunct
respect
tabl
moreov
suggest
associ
pb
categori
muscular
pain
also
observ
chisquar
test
associ
antibodi
test
detect
includ
relationship
presenc
absenc
flu
vaccin
season
look
distribut
pb
n
subject
three
risk
categori
hr
mr
lr
statist
signific
associ
found
particular
expect
pb
individu
mainli
belong
hr
group
mr
group
proport
character
lr
group
differ
statist
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
signific
chisquar
test
see
tabl
also
investig
health
care
occup
categori
logist
regress
data
suggest
medic
doctor
statist
signific
risk
factor
pb
antibodi
test
model
adjust
sex
age
exposur
risk
tabl
moreov
despit
femal
frequent
among
healthcar
profession
male
repres
within
medic
doctor
group
vs
chisquar
test
pvalu
thu
search
presenc
possibl
associ
sex
result
antibodi
test
without
find
signific
evid
neg
result
also
obtain
look
correl
presenceabs
antibodi
report
perform
invas
manoeuvr
aerosol
bronchoalveolar
lavag
intub
swab
patient
suggest
proper
accur
use
individu
protect
devicesdpi
protect
measur
hr
train
personnel
final
twelv
hr
employe
two
male
ten
femal
age
rang
year
old
underw
antibodi
test
second
time
three
ten
day
later
median
valuesix
previous
report
contact
case
intens
antibodi
band
first
assess
show
median
valu
interquartil
rang
iqr
one
individu
intens
second
assess
subject
show
antibodi
intens
remain
subject
decreas
intens
two
assess
repeat
quit
short
time
statist
signific
wilcoxon
test
pair
data
consid
intrins
limit
chromatographi
rapid
test
rapid
decay
detect
antibodi
document
subject
regard
swab
test
one
individu
result
posit
subject
femal
year
old
belong
hr
occup
result
posit
either
presenc
viru
well
antibodi
three
day
sampl
present
mild
clinic
featur
cold
nose
stuffi
dysgeusia
anosmia
last
three
month
report
sign
symptom
outbreak
initi
began
china
spread
mani
countri
rapid
diffus
itali
number
confirm
case
increas
everi
day
complic
situat
evid
median
incub
period
approxim
five
day
gener
peopl
develop
symptom
day
extens
measur
reduc
persontoperson
transmiss
requir
control
current
outbreak
test
window
onto
pandem
spread
without
way
understand
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
anoth
interest
find
work
medic
doctor
repres
healthcar
categori
frequent
associ
presenc
antibodi
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doiorg
probabl
due
peculiar
medic
methodolog
approach
pediatr
patient
includ
parent
prone
amplifi
person
person
contact
moreov
presenc
similar
proport
pb
subject
among
doctor
perform
invas
manoeuvr
might
suggest
proper
accur
use
dpi
protect
measur
hr
train
personnel
conclus
survey
studi
provid
first
time
insight
extent
infect
immun
statu
italian
health
care
worker
popul
ie
motherchild
research
hospit
strengthen
hypothesi
quit
larg
proport
asymptomat
mild
symptomat
peopl
develop
specif
immun
respons
consequ
critic
issu
arous
wide
concern
immun
subject
reinfect
cohort
studi
convalesc
sarscov
patient
reveal
specif
igg
antibodi
neutral
antibodi
peak
month
four
onset
diseas
decreas
gradual
throughout
two
year
followup
sampl
turn
neg
light
preliminari
find
studi
despit
obtain
small
seri
subject
n
indic
possibl
presenc
rapid
decay
antibodi
amount
strengthen
urgent
need
introduct
antibodi
quantit
test
perform
conjunct
nasoor
pharyng
swab
way
apart
preexist
health
condit
potenti
predispos
eg
obes
hypertens
chronic
respiratori
diseas
compromis
immun
statu
believ
might
protect
predispos
genet
variant
gene
recent
describ
potenti
modul
ill
answer
huge
implic
diffus
infect
sinc
expert
believ
continu
spread
across
world
wave
hit
populationcountri
sever
time
reason
present
data
demonstr
necess
start
futur
epidemiolog
activ
aim
increas
number
subject
test
molecular
serolog
assay
follow
univers
monitor
protocol
moreov
introduct
accur
precis
method
measur
antibodi
ie
elisa
assay
help
better
classifi
pb
individu
understand
pandem
spread
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
dataset
complet
anonym
made
avail
chief
medic
offic
team
test
employe
motherchild
research
hospit
irccsburlo
garofolo
conduct
within
surveil
program
establish
italian
prime
minist
decre
requir
ethic
approv
consent
form
prepar
chief
medic
offic
team
sign
particip
author
declar
compet
interest
